CalciMedica: CRACking toxicity

Calcineurin inhibitors are effective in preventing acute organ transplant rejection and treating autoimmune diseases, but their long-term use is associated with renal and hepatic toxicities. CalciMedica Inc. hopes to sidestep these toxicities by developing therapeutics that modulate calcium release-activated calcium channels, key upstream regulators of calcineurin activity.

Both of the calcineurin inhibitors

Read the full 518 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE